Identification
- Generic Name
- Tymazoline
- DrugBank Accession Number
- DB08803
- Background
Tymazoline is a nasal preparation.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Tymazoline (DB08803)
- Weight
- Average: 232.3214
Monoisotopic: 232.157563272 - Chemical Formula
- C14H20N2O
- Synonyms
- Tymazoline
Pharmacology
- Indication
For the treatment of Inflammation of the lining of the nose and paranasal sinuses and allergic inflammation of nasopharyngeal.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Tymazoline is a drug with antihistaminic and sympathomimetic properties. It locally reduces swelling, inflammation and mucosal secretions of the nasal passages.
- Mechanism of action
Thymazen causes vasoconstriction of the nasal mucosa, reducing congestion and thus the swelling of the mucosa. Also reduces the secretions from the nose. Thymazen acts on alpha-adrenergic receptors, which reduces local inflammation of the nasal mucosa especially if their cause is an allergy.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
A large overdose or accidental oral intake, especially in children, may cause excessive sedation with drowsiness, reduced body temperature, heart rate relief and fluctuations in blood pressure and collapse.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareOxymetazoline The absorption of Tymazoline can be decreased when combined with Oxymetazoline. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Thymazen
Categories
- ATC Codes
- R01AA13 — Tymazoline
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Monoterpenoids
- Direct Parent
- Aromatic monoterpenoids
- Alternative Parents
- Monocyclic monoterpenoids / Phenylpropanes / Cumenes / Phenoxy compounds / Phenol ethers / Toluenes / Alkyl aryl ethers / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds show 5 more
- Substituents
- 2-imidazoline / Alkyl aryl ether / Amidine / Aromatic heteromonocyclic compound / Aromatic monoterpenoid / Azacycle / Benzenoid / Carboximidamide / Carboxylic acid amidine / Cumene show 18 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- U993RH5585
- CAS number
- 24243-97-8
- InChI Key
- QRORCRWSRPKEHR-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H20N2O/c1-10(2)12-5-4-11(3)8-13(12)17-9-14-15-6-7-16-14/h4-5,8,10H,6-7,9H2,1-3H3,(H,15,16)
- IUPAC Name
- 2-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-4,5-dihydro-1H-imidazole
- SMILES
- CC(C)C1=C(OCC2=NCCN2)C=C(C)C=C1
References
- General References
- Levrier J, Molon-Noblot S, Duval D, Lloyd KG: A new ex vivo method for the study of nasal drops on ciliary function. Fundam Clin Pharmacol. 1989;3(5):471-82. [Article]
- Lorino AM, Lofaso F, Drogou I, Abi-Nader F, Dahan E, Coste A, Lorino H: Effects of different mechanical treatments on nasal resistance assessed by rhinometry. Chest. 1998 Jul;114(1):166-70. [Article]
- External Links
- Human Metabolome Database
- HMDB0015693
- KEGG Drug
- D07373
- PubChem Compound
- 34154
- PubChem Substance
- 99445273
- ChemSpider
- 31478
- ChEBI
- 134947
- ChEMBL
- CHEMBL2106467
- ZINC
- ZINC000000002232
- PharmGKB
- PA165958422
- Wikipedia
- Tymazoline
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.118 mg/mL ALOGPS logP 3.2 ALOGPS logP 2.64 ChemAxon logS -3.3 ALOGPS pKa (Strongest Basic) 9.26 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 33.62 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 69.54 m3·mol-1 ChemAxon Polarizability 27.29 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9947 Blood Brain Barrier - 0.572 Caco-2 permeable - 0.5359 P-glycoprotein substrate Substrate 0.7787 P-glycoprotein inhibitor I Non-inhibitor 0.8564 P-glycoprotein inhibitor II Non-inhibitor 0.588 Renal organic cation transporter Inhibitor 0.6599 CYP450 2C9 substrate Non-substrate 0.7725 CYP450 2D6 substrate Non-substrate 0.5833 CYP450 3A4 substrate Non-substrate 0.5478 CYP450 1A2 substrate Inhibitor 0.653 CYP450 2C9 inhibitor Non-inhibitor 0.8779 CYP450 2D6 inhibitor Inhibitor 0.8674 CYP450 2C19 inhibitor Non-inhibitor 0.8289 CYP450 3A4 inhibitor Non-inhibitor 0.8562 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6477 Ames test Non AMES toxic 0.78 Carcinogenicity Non-carcinogens 0.9076 Biodegradation Not ready biodegradable 0.9959 Rat acute toxicity 3.2336 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.5936 hERG inhibition (predictor II) Non-inhibitor 0.6603
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 15, 2010 16:48 / Updated at June 12, 2020 16:52